Trials / Completed
CompletedNCT04400201
A Clinical Study of Remimazolam Tosilate in Patients Undergoing Bronchoscopy
A Phase III Clinical Study Evaluating the Efficacy and Safety of Remimazolam Tosilate Compared to Propofol in Patients Undergoing Bronchoscopy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 330 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
A multicenter, randomized, single-blind, active controlled, parallel group study comparing remimazolam tosilate to propofol in patients undergoing bronchoscopy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Remimazolam Tosilate | Intravenous injection at a dose of 0.3mg/kg for sedation induction and continuous intravenous infusion at an initiative dose of 1 mg/kg/h for sedation maintenance. |
| DRUG | Propofol | Intravenous injection at a dose of 1.5\~2.5mg/kg for sedation induction and continuous intravenous infusion at the dose of 0\~12 mg/kg/h for sedation maintenance |
Timeline
- Start date
- 2020-06-15
- Primary completion
- 2020-10-28
- Completion
- 2020-10-30
- First posted
- 2020-05-22
- Last updated
- 2022-08-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04400201. Inclusion in this directory is not an endorsement.